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Role of "lymphotoxin" in the local anti-tumour action
associated wi-th inflammation caused by delayed
hypersensitivity responses or intralesional BCG
I. Variations in response of different syngeneic mouse
tumours
I.B. Parr, L.E. Jackson & P. Alexander1
Institute ofCancer Research, Sutton, Surrey and 'CRC Medical Oncology Unit, Southampton General
Hospital, Southampton.
Summary The anti-tumour effect induced by a delayed hypersensitivity response (DHSR) unrelated to the
tumour or by intra-tumoural inoculation of BCG was studied with 6 syngeneic mouse tumours. The growth
of the tumours was followed i.p. or s.c. in suitably sensitized animals either in the presence or absence of the
specific antigen required to elicit a DHSR. In a Winn-type assay the growth of tumour cells admixed with
sensitized lymphocytes was also determined with and without the eliciting antigens. In addition, the effect of
admixing different amounts of BCG with the tumour cells was studied on the growth of the tumours in vivo.
The different tumours varied widely in their susceptibility to growth inhibition by a DHSR reaction and by
BCG but their order of sensitivity was the same in all of the tests.
Analysis of the effector population in the Winn test coupled *ith the inability to observe an anti-tumour
action in mice with defective T-cell function showed that the effector mechanism involved allergized T-cells or
more probably products released when these were confronted with the specific antigen. In vitro the relative
susceptibility of the different tumour cells to killing by activated macrophages and by NK cells was quite
different to that found for in vivo growth inhibition but the in vitro response to lymphotoxin of the different
tumours paralleled that produced by inflammation in vivo.
The destruction of some local tumours-principally
but not exclusively of the skin-as a result of
inducing persistent inflammation by a delayed-type
hypersensitivity response (DHSR) (Klein, 1968),
inoculation of vaccinia virus (Hunter-Craig et al.,
1970) or intratumoural inoculation of BCG
(Morton et al., 1970) was first observed in man.
This effect can be mimicked in rodents with some,
but not all, syngeneic transplantable tumours. An in
vivo anti-tumour action of a DHSR was demon-
strated in our laboratory by immunizing mice with
BCG and then injecting the eliciting antigen,
purified derivative of tuberculin (PPD) either mixed
with or given one or two days after, inoculation of
tumour cells i.p., i.v., s.c. or i.d. (Alexander, 1973,
and Alexander et al., 1981).
Initially, we ascribed the destruction of tumour
cells at the site of a DHSR reaction to activated
macrophages (Alexander, 1973) but subsequently
found (Parr et al., 1975) in a Winn-type assay, in
which leukocytes from an inflammatory site
(peritoneal cavity) are added to tumour cells in vitro
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and the mixture inoculated into mice, that the
lymphocytes-and not the macrophages were the
principal cytotoxic cells involved. This study raised
the possiiMlty that a cytotoxic lymphokine(s) could
be the,agent responsible for the destruction of
tumour in the midst of an inflammatory reaction.
This investigation addressed itself to the
questions: (a) is the mechanism by which a DHSR
eliminates a local tumour the same as that
responsible for the anti-tumour action of intra-
lesional BCG; and (b) which of the potential anti-
tumour agents present in a DIHSR are responsible
for the in vivo anti-tumour effect? Activated
macrophages, NK cells, allergized lymphocytes or
lymphokines (e.g. lymphotoxin) released when
allergized lymphocytes contact the specific antigen
are all likely to be present in a lesion induced by a
DHSR and all have been shown to be capable of
killing tumour cells in vitro, Alexander (1973),
Wolfe et al. (1976), Granger & Kolb (1968).
Our approach to this problem was to compare in
a series of syngeneic mouse tumours, their
susceptibility to inhibition in vivo (i) by a DHSR (in
both skin and peritoneal cavity), (ii) by intra-
lesional BCG, and (iii) in a Winn assay using cells
from a peritoneal exudate induced by a DHSR.
The combined data strongly support the hypothesis
that a cytotoxic factor elaborated when T-cells
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from sensitized animals meet the specific antigen
and which has the properties ascribed to
lymphotoxin, is responsible for the destruction of
certain tumours by both a DHSR and intra-lesional
BCG.
Materials and methods
Animals
Ten-week old mice C57/Bl and DBA/2 were
supplied by the breeding unit of the Chester Beatty
Research Institute. They were fed the usual diet of
water and mouse chow ad libitum throughout the
experiments.
Tumours
Details of fibrosarcomas FS6, FS1 (C57/B1 mice)
and lymphomas L5178Y (DBA/2) and TLX9
(C57/Bl) were given previously (Parr et al., 1973).
FS29 is a benzpyrene; induced fibrosarcoma, whilst
FS6M1 is a metastatic line which arose after
prolonged passage of FS6. Minimum numbers of
tumour cells necessary for 100% tumour incidence
(at i.d. site) are given in Table IV. All tumours
were adapted to grow in either suspension
(lymphomas) or monolayer (fibrosarcomas) culture
and were maintained in RPMI 1640 medium
supplemented with 10% FBS, sodium pyruvate and
L-glutamine. Early storage of the tumour cells in
liquid N2 as soon as growth was established in vitro
allowed regular returns to the tumour bank after 9-
10 passages. Target cells used in cytotoxicity assays
were taken from serial passage numbers 3-10.
Chemicals
Freeze-dried BCG vaccine (percutaneous: Glaxo
Laboratories Ltd., Greenford, Middlesex, England)
contained 1-3 x 108 viable units per ampoule
equivalent to 3mg (moist weight) organismsml- '. The dose of BCG was 3004g (i.e. -1foth of an
ampoule) except where stated. WSA (Water soluble
fraction of mycobacterial cell walls) was a gift from
Professor Ledere (Institut de Chimie des Substances
Naturelle, Gif-sur-Yvette, France). Purified protein
derivative (PPD) prepared from tubercle bacilli and
supplied undiluted at 105 units ml-' was obtained
from Evans Medical Ltd., Speke, Liverpool. The
usual dose given alone or mixed with tumour was
100 units. 2,4-dinitrophenyl-L-oa-alanine was
purchased from BDH Chemicals Ltd., Poole,
Dorset. Egg albumin and DNP-albumin conjugate
were supplied by Calbiochem-Behring Corps., P.O.
Box 22, Bishops Stortford, England. Coryne-
bacterium parvum was supplied by Wellcome
Reagents, Beckenham, Kent as a killed saline
suspension. Anti Thy 1.2-(C3H mouse monoclonal)
serum was obtained from Searle Diagnostic, High
Wycombe, England.
Preparation ofperitoneal exudate cells
Full details are recorded in Parr (1977). Briefly, PE
cells were taken, unless stated otherwise, from mice
given BCG i.p. 14 days previously, using cooled
siliconized glassware. Nylon-wool fractionated cells
prepared in the absence of serum yielded a
population of small lymphocytes, 90% of which
were killed by incubation with anti Thy 1.2 and
guinea pig complement. On the other hand cell
preparations containing NK cell activity came from
mice given BCG 3 days before. These peritoneal
cells were fractionated on nylon-wool columns in
the presence of serum.
Winn assay
As described, Winn (1961) and Parr et al., (1977)
tumour cells were added in vitro to effector cells at
various ratios and the cell mixture injected s.c. into
syngeneic mice.
NK cell assay
Target cells at 107mI- were labelled with
Na25'CrO4 (1009Ci) for 1 h at 37°, after which
time the cells were washed x 3 with medium 199,
resuspended in RPMI-1640 and incubated for a
further hour at 370. After washing, the cells
104/well were placed in Nunc-u-bottomed microtest
plates with varying numbers of peritoneal exudate
cells (non-adherent fraction) and incubated for 4h
at 370 in a 5% CO2 atmosphere. 5'Cr was
determined in 0.1 ml of supernate (plate was
centrifuged at 200g for 5min) using a Packacd
auto-gamma counter. Per cent specific lysis was
calculated as follows:
" Cr cpm experimental-spontaneous
release (medium only)
=~~~~~~~~ x Maximal release (freezing and
thawing)-spontaneous release
:100
The NK sensitive target-cell line YAC-l incubated
under the above conditions with PE cells at an
effector: target ratio of 20: 1 gave 50% specific
lysis.
Stimulatedgranulocytes
Human polymorphonuclear leucotes prepared from
whole blood by sedimentation through dextran
(5%) were activated by addition of Concanavalin
A(5Mg per well). Assay conditions were the same asLOCAL ANTI-TUMOUR ACTION OF LYMPHOTOXIN 397
for NK cells except that the incubation period was
1.5h. YAC-1 proved to be very sensitive to this
type of effector cell, being 80% lysed by ratio of 5
polymorphs to one YAC-1 cell.
Lymphotoxin
T-cell enriched peritoneal cells taken from mice
given BCG i.p. 14 days previously were incubated
107ml-1 in RPMI+10% FBS with PPD 250 i.u.
ml-' for 24h. The supernatant from this incubate
contained "lymphotoxin" activity as measured
against the sensitive target cell FS6 fibrosarcoma.
Various tumour cells were examined for sensitivity
to "lymphotoxin" lysis in a micro-cytotoxicity test.
Target cells (5x iO0 per well) were seeded into
micro-culture plates (Falcon Micro Test II-3040)
and labelled with ["25I] UdR (O.1yCi per well) for
4h. After thorough washing, "lymphotoxin" (0.1 ml
of various dilutions of supernatant) was added and
the plates incubated for 48-72h at 370 in an
atmosphere of 5% CO2. After centrifugation
[125I]UdR release was measured and % lysis
calculated as follows:
[1251]UdR cpm experimental
oly . -spontaneous release (medium only)
sls Total [125I]UdR cpm release
-spontaneous release
Results
Variation in susceptibility. to DHSR of different
tumours
Table I shows that the inoculation of PPD
interferes to varying extents with the growth of a
range of tumours inoculated i.p. into mice that had
been sensitized to BCG. PPD had no anti-tumour
activity in mice that had not been immunized with
BCG. The tumour most sensitive to DHSR was a
chemically-induced sarcoma FS6 where the growth
of 107 cells could be totally inhibited in BCG-
treated mice by the administration of PPD, whereas
Table I Effect of inducing a DHSR by adding PPD to different syngeneic
murine tumour cells on their growth i.p. in mice sensitized to PPD by prior
immunization with BCGb
% mice (groups of 10) which
7iTmour inoculated: survive 12 weeks after i.p.
Strain of No. ofcells inoculation oftumour cells
Designation origin injected i.p. mixed with PPDa
TLX9
(lymphoma) C57/B1 103 0
L5178Y
(lymphoma) DBA/2 5 x 103 20
104 20
5x104 0
B16
(melanoma) C57/B1 5 x 104 50
10s 40
5x105 0
FS1
(sarcoma) C57/B1 5 x 105 80
106 60
4x 106 60
107 0
FS6
(sarcoma) C57/B1 106 100
4x 106 100
107 100
aEach experiment was controlled by inoculating the same number of
tumour cells into (a) normal mice; (b) BCG-immunized mice; and (c)
tumour cells+PPD into normal mice. The data are not shown as all of the
animals in these control groups died of tumours.
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there was no effect at all on the growth of the
radiation-induced lymphoma TLX9. The magnitude
of the response of the other tumours can be
roughly quantitated by comparing the size of the
inoculum that was rejected in the presence of a
DHSR with that needed to produce a tumour in
normal mice. A protective factor expressed as the
ratio of the number of tumour cells needed to
produce tumours in the presence and in the absence
of an inflammatory reaction ranges progressively in
this series of tumours from greater than 103 for
FS6 to 1 (i.e. no protection) for TLX9.
Figure 1 shows that the different tumours may be
placed in the same order of sensitivity to inhibition
of growth by a DHSR either growing i.p. or in an
s.c. site. In the Winn test (Figure 2) these tumours
are also ranked in the same sequence with regard to
the level of inhibition induced by mixing PPD and
PE cells from mice immunized with BCG with the
tumour cell inoculum before injection i.d. Without
PPD even PE cells 40 times in excess of tumour
cells failed to stop the growth of the most
responsive tumour. In the presence of PPD the
range of sensitivity to a component of the DHSR
(i.e. immune PE cells+PPD) can be expressed as
the ratio of PE: tumour cells needed to stop
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Figure 2 Effect on subcutaneous growth of different
tumours of adding PPD and varying numbers of PE
cells from mice immunized with BCG. (In control
experiments the various tumours grew in 100% of
animals when to the 105 tumour cells were added: (a)
4 x 106 PE cells (i.e. ratio 40: 1) from BCG immunized
mice without PPD; or (b) 4 x 106 PE cells from normal
(i.e. not immunized with BCG) plus PPD.
growth; this ranged from 2;1 down to 40:1 with the
TLX9 being totally refractory.
Comparison of different ways of indusing a DHSR
reaction
178Y + PPD (5/5) Table II shows that DHSR reactions other than
those induced by immunization with BCG and
/ / elicited with PPD were also capable of inhibiting
//,* growth of the FS6 tumour. Again, the anti-tumour
A/ effect was local and occurred at the site where the
eliciting antigen was injected. Mice immunized with
//5,2/,' -egg albumin to which dinitrophenol (DNP-EA) had
,° X"E' ,o been coupled rejected FS6 tumour cells when these
/,, ' were inoculated with either the haptenized protein
-HM,X' , or the protein alone but administration of the
-,' , hapten as DNP-alanine was ineffective. A
-' , pronounced anti-tumour action was also produced
with killed C. parvum when used both as the
immunogen and the eliciting agent. A water soluble
Il~~t , | extract from tubercle bacilli (referred to as Neo-
10 20 30 WSA) could, like DNP-EA and C. Parvum, be used
(d) after inoculation of both as the immunogen and as the eliciting agent
tumour cells for an anti-tumour DHSR. Not unexpectedly,
DHS reaction on sc growth of however, in mice immunized with Neo-WSA-
mours. 106 cells were inoculated unlike those immunized with C. parvum-an anti-
t addition of PPD into mice tumour reaction could also be induced with PPD.
previously with i.p. BCG. DNP-EA, C. parvum and Neo-WSA can also be
s indicate the number of mice shown to induce PE cells which are cytotoxic in the
Winn test (Table III) if the specific antigen is
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Table II Comparison of different antigenic systems in the anti-tumour
action of a DHSR reaction against FS6 sarcoma inoculated i.p.
No. ofmice surviving
Antigen added to 12 weeks after i.p.
Sensitization ofhost tumour inoculum challenge with tumour
None 0/10
lOOMg DNP egg albumin l DNP-egg albumin 8/10
i.p. Day -7 [egg albumin 6/10
JDNP-alanine 0/10
None DNP-egg albumin 0/10
100pg C. parvum } None 0/10 iOOpg. parvu45pg C. parvum 10/10
i.p. Day -14 i100 i.u. PPD 0/10
None 5jg C. parvum 0/10
3 None 0/10
300pg BCG 100 i.u. PPD 10/10
i.p. Day -14 35pg C. parvum 0/10
A None 0/5 300ipg Neo WSA p 5g Neo WSA 4/5
i.p. Day-14 J)100 i.u. PPD 2/5
None 5pg Neo WSA 0/5
Table Ill Anti-tumour action of immune peritoneal exudate cells in a Winn assay (10' FS6
cells injected s.c. with varying numbers of PE cells)-Need for specific antigen to be present
Antigen added to No. ofmice without tumours:
Sensitization ofhost tumour inoculum Ratio ofPE cells to tumour cells
40:1 20:1 10:1 5:1 2:1 1:1
BCG None 0/10 .
300.pg i.p. Day -14 |100 units PPD - 10/10 8/10 4/10 0/10
C. parvum None 0/10.
100u i.p. Day -14 6pg C. parvum 10/10 -
None 0*10 -
DNP-egg albumin DNP-alanine 0/10.
l00pg Day -7 DNP-egg albumin 5/5 4/5 1/5 0/5
egg albumin 5/5 3/5 2/5 0/5
present. It should be noted that as in the direct test
of anti-tumour action (Table II) the complete
antigen DNP-EA or the protein alone (EA) but not
the hapten (DNP-1-alanine) rendered PE cells of
DNP-EA immunized mice cytotoxic in the Winn
test (Table III) if the specific antigen is present.
Similarity ofanti-tumour action o DHSR and intra-
lesional BCG
An anti-tumour action of intra-lesional BCG has
been frequently demonstrated in experimental
tumours by inoculating established skin tumours
with BCG or by adding BCG to tumour cells and
BJ.C.-D
then inoculating the mixture intradermally (Zbar &
Tanaka, 1971, Baldwin et al., 1971). We chose to
measure the relative susceptibility of the series of
tumours to growth inhibition as a result of direct
contact with BCG by inoculating a given number
of tumour cells admixed with varying amounts of
BCG. In this test system the different tumours used
exhibited a wide range of sensitivity (Table IV). An
effect on the growth of FS6 could be shown with as
little as 40pg of BCG, whereas the TLX9 was quite
unaffected by 600pg. The other tumours were
intermediate and when ranked were in the same
order of susceptibility as that to growth inhibition
by a DHSR or in the Winn test.400 I.B. PARR et al.
Table IV Inhibition of intra-dermal tumour growth by addition of BCG to the tumour inoculum:
Variation in the susceptibility ofdifferent syngeneic tumours
Minimum no.
oftumour cells Amount of No. ofmice
to induce 100% No. oftumour BCG without tumour
7llmour tumour takes i.d. cells injected admixed (jug) at 3 mths
TLX9 (C57/B1 lymphoma) 5 x 102 5 x 103 300 0/5
5 x 103 600 0/5
L5178Y (DBA/2 lymphoma) 1i0 106 300 0/5
106 600 3/5
B16 (C57/B1 melanoma) 5x 104 5x 105 100 0/10
5 x 105 300 6/10
FS29 (C57/B1 fibrosarcoma) 5 x104 5 x 105 50 0/10
100 5/10
300 10/10
FS1 (C57/B1 fibrosarcoma) 5 x 10' 5 x 101 50 0/10
100 10/10
300 10/10
FS6M1 (C57/B1 fibrosarcoma) 5 x 10' 5 x i05 50 4/10
100 10/10
FS6 (C57/B1 fibrosarcoma) 5 x 10' 5 x i05 10 0/10
25 4/10
50 6/10
100 10/10
In immune suppressed mice:
FS6 in C57/B1 mice 1i0 None 0/5
treated with Cyclosporin A' 100 1/5
600 2/5
FS6 in random bred nu/nu 105 None 0/5
100 0/5
300 0/5
600 0/5
a80mgkg-'/day p.o. for 18 days starting 4 days before inoculation of tumour cells.
Participation of T-lymphocytes
The involvement of T-cells could be demonstrated
for each of the three procedures used to
demonstrate in vivo an anti-tumour action
associated with inflammation. In the first test
system in which 106 FS6 cells mixed with PPD were
inoculated i.p. into mice immunized with BCG as
described in Table I, tumour growth occurred in
each of the 5 mice if, 2h prior to the inoculation of
the tumour cells and PPD, T-cells in the peritoneal
cavity were killed by administering i.p. 0.1 ml of
1:100 anti Thy 1.2 antibody and 0.1 ml of guinea
pig serum as a source of complement. Inoculation
of complement or antibody alone did not permit
tumour growth in any of the mice (5 per group),
i.e. did not interfere with the anti-tumour action of
the DHSR elicited by PPD.
A direct role of T-cells at the effector level of the
anti-tumour activity of a DHSR has been
demonstrated in the Winn test by selective
depletion of different types of cells from the total
population of PE cells derived from mice
immunized with BCG (Table V). The composition
of the PE cells in mice 14 days after immunization
with BCG has been studied by Parr et al. (1977)
and found to have 30% Thy 1.2 positive cells which
do not adhere to nylon wool even when
fractionated in the absence of serum. After
fractionation on nylon wool (or by adherence to
plastic) 70% of the PE cells are non-adherent but
only half of these are positive for Thy 1.2. From
Table V it is clear that on a per cell basis the cells
which do not adhere to nylon in the absence of
serum and of which 90% are T-cells on the basis of
being lysed by Thy 1.2 antibody and complement,LOCAL ANTI-TUMOUR ACTION OF LYMPHOTOXIN 401
Table V Properties of peritoneal exudate cells from mice sensitized with BCG
responsible for anti-tumour action in Winn-assay against FS6 cells injected s.c.
with PPD'
Source ofP.E. cells
Total population taken:
No. ofmice without tumours:
Ratio of PE cells to tumour cells
40:1 20:1 10:1 5:1 2:1 1:1
3 days 0/5 0/5
5 days 0/5 1/5 1/5 1/5
7 days after immunization 5/5 5/5 3/5 0/5
9 days r with BCG 4/5 4/5 3/5
11 days - - 5/5 4/5 3/5
14 daysJ - - 5/5 5/5
14 days post-BCG:
Treated with anti-macrophage
serum+complement - 10/10 10/10 10/10 4/10 0/10
Non-adherent cells' - - 10/10 10/10 10/10 8/10
+5Gy X-rays - 8/10 6/10 4/10
+30Gy X-rays - - 0/10 -
+anti Thy 1,2+cc - 0/10 - - -
aControls were run in which all of the different PE cell preparations were added
at a ratio of 40: 1 to tumours in the absence of PPD. In every instance 100% of
the mice in the groups developed tumours.
bCells obtained after passage through nylon wool in medium without serum.
90% of the cells were lysed by anti Thy 1,2 antibody + complement.
cTreatment with anti Thy 1,2 antibody alone or complement alone did not
abolish anti-tumour action in the presence of PPD of the non-adherent PE cell'r
are considerably more effective than the total cells
from the PE in inhibiting growth in the presence of
PPD (in a Winn assay). Moreover, the sub-
population (< 10%) of cells fractionated in this way
that are resistant to lysis by Thy 1.2 Ab+C' show
no anti-tumour activity. From this we conclude
that it is allergized T-cells which are responsible for
the PPD-dependent killing of tumour cells by PE
cells in the Winn assay. While the experiments
shown in Table V do not exclude the possibility of
participation by macrophages present in the host
into which the tumour plus PE cell mixture is
inoculated, macrophages present in the PE seem to
play no role. The data shown in Table V on the
timing between immunization with BCG and the
removal of PE cells seem to exclude a role for NK
cells since NK activity of PE cells is maximal at 5
days (Wolfe et al., 1976) after inoculation of BCG
and falls to control level by Day 14 when the PE
cells are at their. most active. Also, the necessity to
expose these cells to the eliciting antigen to obtain
an anti-tumour effect is insonsisternt with a
participation of NK cells.
We, like others (Chung et al., 1973), find that
destruction of tumours by intra-lesional BCG
requires the presence of mature T-cells. We find
(Table IV) that admixture of BCG is much less
effective in preventing the growth of FS6 cells in
mice deprived of T-cells both as a result of genetic
defect (the nude mouse) or as a result of treatment
with the highly effective immunosuppressive agent
Cyclosporin A which interferes with the immune
response by preventing the production of sensitized
T-cells (Bunjes et al., 1982).
Relative sensitivity in vitro of the different tumours
to immunologically non-specific killing by different
effectors
In vitro cells can be killed in an immunological
non-specific manner (i.e. independent of the
recognition by T-cells of antigens on their surface)
by macrophages (probably by a variety of different
mechanisms), stimulated granulocytes, NK cells and
by lymphokines, i.e. "lymphotoxin." While it is
correct to say that these cytotoxic processes are
immunologically non-specific, they are highly
selective in that some cells are much more
vulnerable than others. The order of sensitivity of
different tumour cells is not the same for various
types of killing and we therefore compared the
susceptibilities in vitro of the tumours used in this
investigation to those effector mechanisms which
are most likely to be involved in the in vivo anti-
tumour activity of a DHSR and intra-lesional
BCG. These were NK cells, granulocytes,402 I.B. PARR et al.
macrophages activated by lymphokines (i.e.
macrophage-activating activity (MAF) present in
supernatants of cultures in which T-cells from BCG
sensitized mice were exposed to PPD-Evans, Cox
& Alexander, (1973) and the direct cytotoxicity of
such supernatants which is due to lymphotoxin
(Granger & Kolb, 1968). Data from representative
experiments are summarized in Table VI in which
tumours are listed in order of decreasing
susceptibility to DHSR (both direct and by Winn
assay) and intralesional BCG. Repetition of the
various cytotoxicity assays on different serial
passages of the tumours did not change the ranking
of the various tumour cell lines. It is evident that
the only effector cell tested in vitro, which ranks the
tumours in the same order of sensitivity as observed
in vivo is "lymphotoxin".
Discussion
To identify the effector mechanism(s) by which
some tumours are prevented from growing in the
midst of persistent inflammatory reactions the
relative sysceptibility of different tumours was
compared in experimental protocols which
mimicked treatment procedures that have been (and
perhaps still are) used clinically. These were (i) to
immunize mice with an agent that gives rise to a
DHSR when the appropriate eliciting antigen is
given; in most experiments the tuberculin reaction
was used (i.e. BCG to immunize and PPD to elicit)
but similar results were obtained with DNP
haptenized egg albumin and killed C. parvum where
the same material was used for immunization and
elicitation of the DHSR; (ii) intra-tumoural BCG.
We did not expect that different syngeneic tumours
growing in the same strain of mice would exhibit
such a wide range of sensitivity to both these
procedures. This does however allow deductions
concerning mechanism to be drawn by comparing
the susceptibility of these tumours in different test
systems. Thus it becomes probable that the effector
mechanism responsible for the anti-tumour activity
is the same in a DHSR response as with intra-
lesional BCG.
To determine which of the different leukocytes
present in a DHSR and in the lesion induced by
BCG is mainly responsible for the in vivo
destruction of tumour, PE cells from mice in which
a DHSR was induced in the peritoneum by
injecting the eliciting antigen i.p. were added to
tumour cells and the mixture injected. Subsequent
tumour growth was assayed in groups in which the
ratio of PE to tumour cells was varied-i.e. a Winn
assay. That this was a relevant model to study the
anti-tumour action ofinflammation is apparent from
the fact that in this Winn assay the tumours were
ranked in the same order of susceptibility as in the
direct DHSR and intra-lesional BCG (see Figure 2).
Table VI Susceptibility in vitro of the different tumoursa to different
immunologically non-specific leukocyte effectors
% lysis by:
Tumour NKb MAF activatedc Stimulatedd "Lymphotoxin" Dilutedc
cells used cells macrophages granulocytes 1:64 1:256
FS6 15 21 9 100 95
FS29 27 26 13 65 47
B16 20 12 11 8 4
L5178Y 19 50 28 6 0
TLX9 4 62 18 0 0
aThe relative sensitivity in vivo of the different tumours to DHSR and to BCG
given mixed with tumour cells is FS>FS29>B16>L5178Y>TLX9.
bBy 4h 51Cr release from labelled tumour cells using PE cells (ratio 20 PE: I
tumour cell) taken 5 days after i.p. BCG. At this time NK activity (as assessed on
YAC-1 cells) is at a maximum.
Fig_%Specific 51Cr release.
cSupematant from incubates of T-cell enriched PE cells (removed 14 days after
i.p. BCG) incubated with PPD for 24h at 370 was:
(a) used to activate macrophage monolayers incubated with IUDR labelled
tumour cells for 48h. Fig_%Specific IUDR Release.
(b) Added to monolayers of IUDR labelled tumour cells, which were then
incubated for 2-3 days at 37°. Fig Specific IUDR release.
dHuman polymorphs activated by addition of Con A were incubated (at ratio 5
polymorphs:1 target cell) for 1.5h. Fig_%Specific 5"Cr release.LOCAL ANTI-TUMOUR ACTION OF LYMPHOTOXIN 403
From the results shown in Table V it can be
deduced that a cell responsible for initiating tumour
destruction in the Winn assay is a radio-resistant
allergized T-cell that has been exposed to the
approriate antigen. The Winn test data do not
allow us to decide whether such a cell is
immediately cytotoxic, or whether the effect is
caused by a lymphokine. If it is caused by a
lymphokine, then this could be directly cytotoxic or
it could arm macrophages provided by the host
which has been inoculated with the mixture of
tumour cells and allergized T-cells that have been
exposed to antigen. In the three in vivo situations
studied, i.e. inoculation of tumour cells into the site
of the DHSR, intra-lesional BCG and the
particular Winn test used here, macrophage-
activating factor (MAF) will be produced and
macrophages, rendered cytotoxic, will be present,
yet from the data shown in Table VI these do not
appear to contribute significantly to the anti-
tumour action of inflammation. Macrophages
armed with MAF are most effective in killing those
tumour cells, the growth of which in vivo is least
susceptible to inflammation. On the other hand, the
direct cytotoxic activity of the lymphokine
containing supernatants (i.e. "lymphotoxin")
mimicks closely the in vivo response. A detailed
study of the cytotoxic action of T-cells and PPD
from BCG treated mice and the optimum condition
for obtaining "lymphotoxin" activity will be
reported subsequently.
The available data are consistent with the
hypothesis that the interference by inflammation
with local tumour growth is brought about by the
formation of lymphotoxin at the site of
inflammation. These experiments suggest that it is
worthwhile to explore means of making
lymphotoxin available systemically to treat
disseminated malignant cells. Sensitivity to
lymphotoxin is probably not infrequent with human
tumours since, when they are present in the skin,
many tumours of different histological type have
been found to respond to the induction of a DHSR
or to intra-lesional BCG.
This investigation has been supported by a Programme
Grant of the Medical Research Council.
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